A social significance of the pharmacogenetic testing in Ukraine on the example of the CYP2B6 gene participating in the nicotine metabolism

Authors

DOI:

https://doi.org/10.24959/nphj.18.2204

Keywords:

Pharmacogenetic testing, CYP2B6 gene, nicotine addiction, Ukraine

Abstract

The study of the pharmacogenetic testing in Ukraine on the example of the gene CYP2B6 participating in the nicotine metabolism is currently topical and socially significant problem.
Aim. To determine the potential sample among the residents of Ukraine, for which the therapeutic effect of the treatment of nicotine addiction with bupropion will be the most effective considering polymorphism of the CYP2B6 gene.
Materials and methods. Genotyping of the participants in the study with respect to CYP2B6 polymorphism (rs3745274) was carried out using a polymerase chain reaction. In addition to genotyping, the survey participants filled in questionnaires that reflected their socio-demographic data, as well as the lifestyle, duration and frequency of smoking.
Results and discussion. In the course of the studies conducted it has been found that approximately 7 % of the population has a genetic variant of CYP2B6 predisposing to smoking. The same persons are a potential target audience for conducting the personalized therapy.
Conclusions. Prior the pharmacotherapy it is advisable to conduct the pharmacogenetic testing, which will reduce the cost of therapy and the risk of side effects in the future.

References

Sychev, D. A. (2011). Farmakogeneticheskoe testirovanie: klinicheskaia interpretatciia rezultatov. Moscow, 88.

Sychev, D. A., Ignatev, I. V., Ramenskaia, G. V., Kukes, V. G. (2007). Klinicheskaia farmakogenetika. Moscow: GEOTAR–MEDIA, 248.

Verde, Z., Santiago, C., Rodríguez González–Moro, J. M., de Lucas Ramos, P., López Martín, S., Bandrés, F., Gómez–Gallego, F.

(2011). “Smoking Genes”: A Genetic Association Study. PLoS ONE, 6 (10), e26668. doi: 10.1371/journal.pone.0026668

Website of the World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs339/en/

Tomaz, P. R. X., Santos, J. R., Issa, J. S., Abe, T. O., Gaya, P. V., Krieger, J. E., Santos, P. C. J. L. (2015). CYP2B6 rs2279343 polymorphism

is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, 71 (9),

–1073. doi: 10.1007/s00228–015–1896–x

Koegelenberg, C. F. N., Noor, F., Bateman, E. D., van Zyl–Smit, R. N., Bruning, A., O’Brien, J. A., Irusen, E. M. (2014). Efficacy of

Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation. JAMA, 312 (2), 155.

doi: 10.1001/jama.2014.7195

Elrashidi, M. Y., Ebbert, J. O. (2014). Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opinion on Emerging

Drugs, 19 (2), 243–260. doi: 10.1517/14728214.2014.899580

Piné–Abata, H., McNeill, A., Murray, R., Bitton, A., Rigotti, N., Raw, M. (2013). A survey of tobacco dependence treatment services in

countries. Addiction, 108 (8), 1476–1484. doi: 10.1111/add.12172

Elbe, D., Bezchlibnyk–Butler, K. Z., Virani, A. S., Procyshyn, R. M. (2014). Pharmacotherapy for Nicotine/Tobacco Use Dependence.

Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 3d. Hogrefe Publishing, 329.

Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., Epstein, L. (2002). Pharmacogenetic investigation of smoking

cessation treatment. Pharmacogenetics, 12 (8), 627–634. doi: 10.1097/00008571–200211000–00007

Filiptsova, O. V., Kobets, M. N., Kobets, Yu. N, Timoshyna, I. A. (2017). SNP polymorphism of CYP1A2 (rs762551) and CYP2B6

(rs3745274) in the Ukrainian population: a pilot study. From genomics to therapy. Barcelona, Spain, 80.

Walsh, P. S., Metzger, D. A., Higuchi, R. (1991). Chelex 100 as a medium for extraction of DNA for PCR–based typing from forensic

material. BioTechniques, 10, 506–513.

Masebe, T. M., Bessong, P. O., Nwobegahay, J., Ndip, R. N., Meyer, D. (2012). Prevalence of MDR1 C3435T and CYP2B6 G516T

Polymorphisms among HIV–1 Infected South African Patients. Disease Markers, 32 (1), 43–50. doi: 10.1155/2012/453479

Chislo kurilshchikov v Ukraine stabilizirovalos na urovne 24%. Available at: https://zn.ua/UKRAINE/chislo–kurilschikov–v–ukraine–

stabilizirovalos–na–urovne–24–202795_.html

Spravochnaia aptek. Available at: https://www.spravka–apteka.com.ua/ziban–price/

All tests – take tests in medical laboratory “Synevo”. Available at: https://www.synevo.ua/en/analizy/vse–analizy/

Downloads

Published

2018-05-31

Issue

No. 2(94) (2018)

Section

Organization and Economy of Pharmacy

License

Copyright (c) 2018 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).